Integrated Filing — IndAS



General information about company
Scrip Code 532321
NSE Symbol ZYDUSLIFE
MSEI Symbol NOTLISTED
ISIN INE010B01027
Name of company ZYDUS LIFESCIENCES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 12-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 01-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-Aug-2025   11:50:00
End date and time of board meeting 12-Aug-2025   12:55:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 65737000000
Other income 1549000000
Total income 67286000000
2 Expenses
(a) Cost of materials consumed 12189000000
(b) Purchases of stock-in-trade 6582000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -876000000
(d) Employee benefit expense 10052000000
(e) Finance costs 847000000
(f) Depreciation, depletion and amortisation expense 2381000000
(f) Other Expenses
1 Other expenses 17476000000 17476000000
2 Net (gain)/ loss on foreign currency transactions -571000000 -571000000
Total other expenses 16905000000
Total expenses 48080000000
3 Total profit before exceptional items and tax 19206000000
4 Exceptional items 0
5 Total profit before tax 19206000000
6 Tax expense
7 Current tax 2307000000
8 Deferred tax 2033000000
9 Total tax expenses 4340000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 14866000000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 344000000
16 Total profit (loss) for period 15210000000
17 Other comprehensive income net of taxes 49000000
18 Total Comprehensive Income for the period 15259000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 14668000000
Total profit or loss, attributable to non-controlling interests 542000000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 14717000000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 542000000
21 Details of equity share capital
Paid-up equity share capital 1006000000
Face value of equity share capital 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 14.58
Diluted earnings (loss) per share from continuing operations 14.58
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 14.58
Diluted earnings (loss) per share from continuing and discontinued operations 14.58
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals 57162000000 57162000000
2 Consumer Products 8575000000 8575000000
Total Segment Revenue 65737000000
Less: Inter segment revenue
Revenue from operations 65737000000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals 17772000000 17772000000
2 Consumer Products 1434000000 1434000000
Total Profit before tax 19206000000
i. Finance cost 0 0
ii. Other Unallocable Expenditure net off Unallocable income 0 0
Profit before tax 19206000000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals 317354000000 317354000000
2 Consumer Products 63968000000 63968000000
Total Segment Asset 381322000000 381322000000
Un-allocable Assets 0 0
Net Segment Asset 381322000000 381322000000
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals 96479000000 96479000000
2 Consumer Products 6001000000 6001000000
Total Segment Liabilities 102480000000 102480000000
Un-allocable Liabilities 0 0
Net Segment Liabilities 102480000000 102480000000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -31000000 -31000000
Total Amount of items that will not be reclassified to profit and loss -31000000
2 Income tax relating to items that will not be reclassified to profit or loss -17000000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 88000000 88000000
2 Share of OCI of joint ventures (net of tax) -25000000 -25000000
Total Amount of items that will be reclassified to profit and loss 63000000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 49000000